U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07684144) titled 'Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)' on June 29.
Brief Summary: The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
Study Start Date: July 29
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Diabetes Mellitus, Type 2
Intervention:
DRUG: Maridebart Cafraglutide
Administered subcutaneously.
DRUG: Placebo
Administered subcutaneously.
Recr...